Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313219 | 1.00 | MEN1 (0.49) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL309863 | 0.86 | LMNA (0.61) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL8008016 | 0.86 | PTGS1 (0.59) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL4974489 | 0.83 | MEN1 (0.40) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL11027196 | 0.80 | MEN1 (0.52) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL69389 | 0.79 | ALDH1A1 (0.60) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL9265700 | 0.79 | ALDH1A1 (0.60) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL593064 | 0.79 | CYP19A1 (0.62) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL10165092 | 0.78 | TSHR (0.65) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL16952226 | 0.78 | ALOX5 (0.50) | MEN1KMT2AHTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118724855-A | Coumarin HDAC6 inhibitor and preparation method and application thereof | 四川卫生康复职业学院 | 2024-10-01 | — | — | CN | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| US-20140296208-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2014076484-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | WU YONG-QIAN (US) | 2004-08-12 | — | — | US | disclosed |
| US-6656971-B2 | Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions | GUILFORD PHARMACEUTICALS INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1360173-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002059080-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885HTT 2464/4885 |
| US-20080015222-A1 | New Heterocyclic Amides | AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 1446/4885KMT2A 2077/4885HTT 552/4885 |
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | MEN1 4867/4885KMT2A 4618/4885HTT 2932/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885HTT 2464/4885 |
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | MEN1 2064/4885KMT2A 2364/4885HTT 3852/4885 |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | MEN1 3687/4885KMT2A 1519/4885HTT 2953/4885 |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | MEN1 4867/4885KMT2A 4618/4885HTT 2932/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885HTT 2464/4885 |
| US-20140296208-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MEN1 4275/4885KMT2A 1737/4885HTT 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.